There’s a lot to be optimistic about in the Technology sector as 3 analysts just weighed in on PagerDuty (PD – Research Report), Veeva Systems (VEEV – Research Report) and Bio-Techne (TECH – Research Report) with bullish sentiments. PagerDuty (PD) Robert W. Baird analyst Robert Oliver  maintained a Buy rating on PagerDuty on June 22 and set a price target of $32.00. The company’s shares closed last Friday at $21.39, close to its 52-week low of $19.51. According to TipRanks.com, Oliver is a 4-star analyst with an average return of 6.7% and a 51.1% success rate. Oliver covers the Technology sector, focusing on stocks such as Aspen Technology, Inc., Tyler Technologies, and Thryv Holdings. The word on The Street in general, suggests a Moderate Buy analyst consensus rating for PagerDuty with a $30.57 average price target.
		  See today’s best-performing stocks on TipRanks >> Veeva Systems (VEEV) In a report issued on June 22, Stephanie Davis  from SVB Securities reiterated a Buy rating on Veeva Systems, with a price target of $233.00. The company’s shares closed last Friday at $200.76. According to TipRanks.com, Davis ‘ ranking currently consits of 0 on a 0-5 ranking scale, with an average return of -4.1% and a 41.9% success rate. Davis covers the Healthcare sector, focusing on stocks such as Tabula Rasa HealthCare, NextGen Healthcare, and GoodRx Holdings. Veeva Systems has an analyst consensus of Moderate Buy, with a price target consensus of $210.55, implying a 5.3% upside from current levels. In a report issued on June 23, Barclays also initiated coverage with a Buy rating on the stock with a $225.00 price target.
		  Bio-Techne (TECH) SVB Securities analyst Puneet Souda  maintained a Buy rating on Bio-Techne on June 22. The company’s shares closed last Friday at $76.62. According to TipRanks.com, Souda has currently 0 stars on a ranking scale of 0-5 stars, with an average return of -7.9% and a 38.4% success rate. Souda covers the Healthcare sector, focusing on stocks such as AbCellera Biologics, Castle Biosciences, and Guardant Health. Currently, the analyst consensus on Bio-Techne is a Strong Buy with an average price target of $96.00. TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
		   Read More on PD:   Indices Commodities Currencies Stocks